Anzeige
Meldung des Tages: Game Changer! Steht hier jetzt die strukturelle Neubewertung nach einem Strategiewechsel bevor?

Nektar Therapeutics Aktie News

Aktie
WKN:  A419UB ISIN:  US6402683063 US-Symbol:  NKTR Branche:  Biotechnologie Land:  USA
31,20 €
-0,2 €
-0,64%
09:24:05 Uhr
Depot/Watchlist
Marktkapitalisierung *
7,03 Mrd. €
Streubesitz
27,94%
KGV
-5,04
Index-Zuordnung
-

Nektar Therapeutics News

01.07.25 - PR Newswire
Nektar Therapeutics Announces Pricing of $100 Million Public Offering
Nektar Therapeutics Announces Pricing of $100 Million Public Offering PR Newswire
30.06.25 - PR Newswire
Nektar Therapeutics Announces Proposed Public Offering
Nektar Therapeutics Announces Proposed Public Offering PR Newswire
24.06.25 - PR Newswire
REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis
REZOLVE-​AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-​to-Severe Atopic Dermatitis PR Newswire
23.06.25 - PR Newswire
Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025
Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-​AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on ...
13.05.25 - PR Newswire
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference PR Newswire
08.05.25 - PR Newswire
Nektar Therapeutics Reports First Quarter 2025 Financial Results
Nektar Therapeutics Reports First Quarter 2025 Financial Results PR Newswire
01.05.25 - PR Newswire
Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets PR Newswire
20.03.25 - PR Newswire
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference PR Newswire
12.03.25 - PR Newswire
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire
05.03.25 - PR Newswire
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Fourth Quarter and Year-​Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets PR Newswire
26.02.25 - PR Newswire
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-​AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-​to-Very Severe Alopecia ...
24.02.25 - PR Newswire
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th PR Newswire
24.02.25 - PR Newswire
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus PR Newswire
10.02.25 - PR Newswire
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-​to-Severe Atopic Dermatitis PR Newswire

Newssuche

Videos

newspaper
01:40 Uhr 0,00%
Wahnsinn! Warum Daytrader im FDAX oft verlieren
Ab Montag, dem 2. Februar börsentäglich ab 18 Uhr - FEIERABEND-​TRADING! Echte Trades auf Basis ... Mehr »